What is Arcutis Biotherapeutics Inc (ARQT) Stock Return on Shareholders’ Capital?

With 4.25 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.77 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.46 whereas the lowest price it dropped to was $7.99. The 52-week range on ARQT shows that it touched its highest point at $13.17 and its lowest point at $1.76 during that stretch. It currently has a 1-year price target of $18.00. Beta for the stock currently stands at 1.17.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARQT was up-trending over the past week, with a rise of 3.17%, but this was down by -19.43% over a month. Three-month performance surged to 17.83% while six-month performance rose 326.77%. The stock lost -19.35% in the past year, while it has gained 151.70% so far this year. For the next quarter, that number is -0.62. This implies an EPS growth rate of 39.86% for this year and 38.27% for next year. EPS is expected to grow by 9.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -48.07%.

Float and Shares Shorts:

At present, 115.53 million ARQT shares are outstanding with a float of 97.76 million shares on hand for trading. On 2024-04-30, short shares totaled 21.69 million, which was 1877.0 higher than short shares on 1711584000. In addition to Mr. Todd Franklin Watanabe M.A. as the firm’s President, CEO & Director, Dr. Bhaskar Chaudhuri Ph.D. serves as its Co-Founder & Independent Director.

Institutional Ownership:

Through their ownership of 0.99424005 of ARQT’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, ARQT reported revenue of $13526000.0 and operating income of -$61169000.0. The EBITDA in the recently reported quarter was -$58112000.0 and diluted EPS was -$0.72.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARQT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.